Nantahala Capital Management LLC Takes $846,000 Position in Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)

Nantahala Capital Management LLC bought a new position in shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 547,804 shares of the company's stock, valued at approximately $846,000. Nantahala Capital Management LLC owned approximately 1.64% of Reneo Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Reneo Pharmaceuticals during the second quarter worth approximately $27,000. Pale Fire Capital SE lifted its position in shares of Reneo Pharmaceuticals by 102.7% in the 4th quarter. Pale Fire Capital SE now owns 30,100 shares of the company's stock valued at $48,000 after acquiring an additional 15,249 shares in the last quarter. Marquette Asset Management LLC purchased a new stake in shares of Reneo Pharmaceuticals in the 1st quarter valued at approximately $122,000. Vestal Point Capital LP purchased a new stake in shares of Reneo Pharmaceuticals in the 4th quarter valued at approximately $640,000. Finally, Highbridge Capital Management LLC lifted its position in shares of Reneo Pharmaceuticals by 6.5% in the 2nd quarter. Highbridge Capital Management LLC now owns 2,915,376 shares of the company's stock valued at $4,402,000 after acquiring an additional 178,806 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors.

Reneo Pharmaceuticals Stock Performance

Shares of NASDAQ:RPHM traded up $0.01 during mid-day trading on Tuesday, hitting $1.71. The stock had a trading volume of 251,267 shares, compared to its average volume of 248,962. The company has a market cap of $57.15 million, a PE ratio of -0.78 and a beta of 0.19. Reneo Pharmaceuticals, Inc. has a 12-month low of $0.98 and a 12-month high of $9.21. The company's 50 day moving average is $1.47 and its 200-day moving average is $1.59.

Reneo Pharmaceuticals (NASDAQ:RPHM - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. On average, equities research analysts predict that Reneo Pharmaceuticals, Inc. will post -0.65 EPS for the current fiscal year.

Insider Activity at Reneo Pharmaceuticals

In related news, major shareholder Braden Michael Leonard purchased 29,600 shares of Reneo Pharmaceuticals stock in a transaction dated Tuesday, September 24th. The stock was bought at an average price of $1.41 per share, for a total transaction of $41,736.00. Following the completion of the acquisition, the insider now directly owns 3,388,649 shares of the company's stock, valued at $4,777,995.09. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. In the last three months, insiders have bought 256,239 shares of company stock worth $355,105. 17.90% of the stock is owned by insiders.

About Reneo Pharmaceuticals

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.